

CURRENT PERSPECTIVES IN HAEMATOLOGICAL MALIGNANCIES 2018

LONDON : Wednesday 4th July

Cavendish Conference Centre, Duchess Mews W1G 9DT

Chairs: Dr George Follows and Professor Graham Jackson

GLASGOW : Wednesday 10th October

The Lighthouse, 11 Mitchell Lane G1 3NU

Chairs: Dr Anne Parker and Professor Graham Jackson

MANCHESTER : Thursday 11th October

Manchester Conference Centre, Sackville Street M1 3BB

Chairs: Dr Mike Dennis and Professor Tim Illidge

BRISTOL : Thursday 22nd November

Doubletree by Hilton, Bristol City Centre, Redcliffe Way BS1 6NJ

Chairs: Dr Stephen Robinson and Dr Andrew McMillan

TOPICS:

The impact of the new licensed therapies in AML

CLL - heading for a cure?

Myeloproliferative neoplasms - current thinking

Continuous therapy in myeloma - the future

High risk and resistant CML: new diagnostic tools and treatment approaches

DEBATES:

ECHELON 1 : Brentuximab should be used first line in advanced Hodgkin lymphoma

GALLIUM : Obinutuzumab, not rituximab, should be used first line for patients with symptomatic follicular lymphoma

CONFIRMED SPEAKERS:

Dr Mike Dennis Christie Hospital, Manchester

Dr George Follows Addenbrooke's Hospital, Cambridge

Professor Claire Harrison Guy's and St Thomas' Hospital, London

Professor Tim Illidge Christie Hospital, Manchester

Professor Graham Jackson NCCC, Newcastle

Dr Steve Knapper University Hospital of Wales, Cardiff

Dr Andrew McMillan Nottingham City Hospital

Dr Wendy Osborne Freeman Hospital, Newcastle

Dr Hugues de Lavallade King's College Hospital, London

Dr Graham Collins Oxford University Hospitals

REGISTRATION: LONDON - 4th July 2018

STANDARD (until 19 th June 2018)	LATE (from 20 th June 2018)
Consultants: £72 Trainees/Nurses: £60 20 free places available for Trainees/Nurses	£108

Registration fees are inclusive of VAT at 20%

Online registration for the London meeting is now open at www.hartleytaylor.co.uk

To register your interest in attending the meetings in Glasgow, Manchester or Bristol, or if you have any other questions, please contact alex@hartleytaylor.co.uk



The sponsors have had no influence over the content of the agenda or speaker selection